News & Updates

The novel potassium-competitive acid blocker zastaprazan (JP-1366) appears to have a rapid and potent gastric acid-suppressive effect, with a single oral dose up to 60 mg and multiple oral doses up to 40 mg being safe and well tolerated, according to a study.

A weight-based dose of extended-release (XR) tacrolimus appears inadequate in predicting a therapeutic level among kidney transplant recipients due to the wide interpatient variability, according to a study.

In the treatment of patients with acute coronary syndrome receiving dual antiplatelet therapy during the acute phase, oral rivaroxaban appears to compare favourably with subcutaneous enoxaparin in terms of bleeding and major adverse cardiovascular event risks, according to a study.

Septic shock patients, particularly those with ongoing tachycardia, who are treated with phenylephrine appears to be at greater risk of mortality, suggests a study.

Clinicians should consider de-escalating combination therapy with immunomodulators to a monotherapy after 1 year in patients with inflammatory bowel disease (IBD), says an expert at Crohn’s and Colitis Congress 2023.

Treatment with a single oral dose of azithromycin, given to women in labour who were planning a vaginal birth, significantly reduced the risk of maternal death or sepsis, according to the A-PLUS* trial presented at SMFM 2023.